Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer
Table 1
Characteristics of participants and their laboratory values.
Characteristics
Healthy controls ()
Patients with benign thyroid nodule ()
Patients with thyroid cancer ()
Age (years)
47.7 ± 16.2
48.6 ± 18.4
49.5 ± 20.1
Male (, %)
25 (47.2%)
34 (49.3%)
31 (54.4%)
Female (, %)
28 ( 52.8%)
35 (50.7%)
26 (45.6%)
Tg (ng/mL)
10.3 ± 11.4
16.4 ± 14.3
109.3 ± 76.3
FT4 (pmol/L)
14.2 ± 4.1
15.1 ± 3.9
16.5 ± 4.6
TSH (IU/mL)
3.4 ± 1.9
3.5 ± 2.1
3.7 ± 3.2
VAP-1 (ng/mL)
683.7 ± 309.2
625.7 ± 304.1
372.3 ± 238.5
Diabetes (, %)
—
4 (5.8%)
5 (7.2%)
Hepatic disease (, %)
—
3 (4.3%)
2 (3.0%)
Thyroid cancer stage
I/II (, %)
—
—
41 (71.9%)
III/IV (, %)
—
—
16 (28.1%)
Data are presented as the mean ± SD. < 0.01 versus control. Tg: thyroglobulin; FT4: free thyroxine; TSH: thyroid stimulating hormone. VAP-1: vascular adhesion protein-1.
